v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Operating expenses:        
Research and development $ 34,532 $ 14,142 $ 78,046 $ 302,342
General and administrative 23,912 13,965 63,410 33,340
Total operating expenses 58,444 28,107 141,456 335,682
Loss from operations (58,444) (28,107) (141,456) (335,682)
Other income (expense):        
Interest income 4,607 1,731 12,886 3,073
Other income 0 4,149 0 4,149
Change in fair value of warrant liabilities (32,890) (790,457) (240,549) (2,090,379)
Total other expense, net (28,283) (784,577) (227,663) (2,083,157)
Net loss $ (86,727) $ (812,684) $ (369,119) $ (2,418,839)
Net loss per share attributable to common stockholders, basic $ (1.45) $ (121.63) $ (7.05) $ (378.11)
Net loss per share attributable to common stockholders, diluted $ (1.45) $ (121.63) $ (7.05) $ (378.11)
Weighted-average common shares outstanding, basic 59,669,730 6,681,794 52,389,596 6,397,121
Weighted-average common shares outstanding, diluted 59,669,730 6,681,794 52,389,596 6,397,121
Other comprehensive loss:        
Unrealized loss on available for sale marketable securities $ (923) $ (2) $ (1,886) $ (10)
Total other comprehensive loss: (923) (2) (1,886) (10)
Comprehensive loss $ (87,650) $ (812,686) $ (371,005) $ (2,418,849)